Aktis Oncology (NASDAQ:AKTS) Shares Cross Below 50 Day Moving Average – Here’s What Happened

Shares of Aktis Oncology (NASDAQ:AKTS) crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $19.47 and traded as low as $17.19. Aktis Oncology shares last traded at $18.63, with a volume of 540,744 shares.

Analysts Set New Price Targets

Several brokerages have commented on AKTS. Wall Street Zen raised Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. Bank of America initiated coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set a “buy” rating and a $34.00 target price for the company. HC Wainwright initiated coverage on shares of Aktis Oncology in a research note on Monday, March 9th. They set a “buy” rating and a $30.00 target price for the company. Leerink Partners assumed coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 price target on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $31.25.

Aktis Oncology Stock Up 2.5%

The firm’s fifty day moving average is $19.47.

Insiders Place Their Bets

In other news, major shareholder Ansbert Gadicke bought 1,112,777 shares of the stock in a transaction on Monday, January 12th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $20,029,986.00. Following the acquisition, the insider owned 10,260,064 shares of the company’s stock, valued at $184,681,152. This represents a 12.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Vida Ventures Ii, Llc purchased 835,000 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $15,030,000.00. Following the transaction, the insider directly owned 5,671,825 shares in the company, valued at approximately $102,092,850. This represents a 17.26% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders bought 6,117,776 shares of company stock worth $110,119,968.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.